HRP20221294T1 - Neuroaktivni steroidi, njihovi pripravci i uporabe - Google Patents
Neuroaktivni steroidi, njihovi pripravci i uporabe Download PDFInfo
- Publication number
- HRP20221294T1 HRP20221294T1 HRP20221294TT HRP20221294T HRP20221294T1 HR P20221294 T1 HRP20221294 T1 HR P20221294T1 HR P20221294T T HRP20221294T T HR P20221294TT HR P20221294 T HRP20221294 T HR P20221294T HR P20221294 T1 HRP20221294 T1 HR P20221294T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical preparation
- administered
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 2
- 150000003431 steroids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 201000006517 essential tremor Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hospice & Palliative Care (AREA)
Claims (15)
1. Spoj formule:
[image]
za uporabu u postupku za liječenje esencijalnog tremora kod subjekta kojem je to potrebno, koji obuhvaća primjenu spoja kod subjekta.
2. Spoj za uporabu kao u patentnom zahtjevu 1, naznačen time što se spoj primjenjuje oralno, subkutano, intravenski ili intramuskularno.
3. Spoj za uporabu kao u patentnom zahtjevu 1, naznačen time što se spoj primjenjuje kronično.
4. Spoj za uporabu kao u patentnom zahtjevu 2, naznačen time što se spoj primjenjuje oralno.
5. Spoj za uporabu kao u patentnom zahtjevu 2, naznačen time što se spoj primjenjuje intravenski.
6. Farmaceutski prihvatljiva sol spoja formule:
[image]
za uporabu u postupku za liječenje esencijalnog tremora kod subjekta kojem je to potrebno, koji obuhvaća primjenu farmaceutski prihvatljive soli spoja kod subjekta.
7. Farmaceutski prihvatljiva sol za uporabu kao u patentnom zahtjevu 6, naznačena time što se farmaceutski prihvatljiva sol primjenjuje oralno, subkutano, intravenski ili intramuskularno.
8. Farmaceutski prihvatljiva sol za uporabu kao u patentnom zahtjevu 6, naznačena time što se farmaceutski prihvatljiva sol primjenjuje kronično.
9. Farmaceutski prihvatljiva sol za uporabu kao u patentnom zahtjevu 7, naznačena time što se farmaceutski prihvatljiva sol primjenjuje oralno.
10. Farmaceutski prihvatljiva sol za uporabu kao u patentnom zahtjevu 7, naznačena time što se farmaceutski prihvatljiva sol primjenjuje intravenski.
11. Farmaceutski pripravak koji sadrži spoj formule:
[image]
i farmaceutski prihvatljiv ekscipijens za uporabu u postupku za liječenje esencijalnog tremora kod subjekta kojem je to potrebno, koji obuhvaća primjenu pripravka kod subjekta.
12. Farmaceutski pripravak za uporabu kao u patentnom zahtjevu 11, naznačen time što se farmaceutski pripravak primjenjuje oralno, subkutano, intravenski ili intramuskularno.
13. Farmaceutski pripravak za uporabu kao u patentnom zahtjevu 11, naznačen time što se farmaceutski pripravak primjenjuje kronično.
14. Farmaceutski pripravak za uporabu kao u patentnom zahtjevu 12, naznačen time što se farmaceutski pripravak primjenjuje oralno.
15. Farmaceutski pripravak za uporabu kao u patentnom zahtjevu 12, naznačen time što se farmaceutski pripravak primjenjuje intravenski.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014078820 | 2014-05-29 | ||
| EP20171670.1A EP3705488B1 (en) | 2014-05-29 | 2015-05-29 | Neuroactive steroids, compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221294T1 true HRP20221294T1 (hr) | 2023-03-03 |
Family
ID=54698130
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221294TT HRP20221294T1 (hr) | 2014-05-29 | 2015-05-29 | Neuroaktivni steroidi, njihovi pripravci i uporabe |
| HRP20201126TT HRP20201126T1 (hr) | 2014-05-29 | 2020-07-17 | Neuroaktivni steroidi, njihovi pripravci i uporabe |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201126TT HRP20201126T1 (hr) | 2014-05-29 | 2020-07-17 | Neuroaktivni steroidi, njihovi pripravci i uporabe |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US20180179247A1 (hr) |
| EP (3) | EP3705488B1 (hr) |
| JP (4) | JP6652934B2 (hr) |
| KR (2) | KR102494061B1 (hr) |
| CN (3) | CN106661078A (hr) |
| AR (2) | AR100691A1 (hr) |
| AU (4) | AU2015266447A1 (hr) |
| CA (1) | CA2949720A1 (hr) |
| CY (1) | CY1124109T1 (hr) |
| DK (2) | DK3705488T3 (hr) |
| ES (2) | ES2805598T3 (hr) |
| HR (2) | HRP20221294T1 (hr) |
| HU (2) | HUE059829T2 (hr) |
| IL (3) | IL292461B2 (hr) |
| JO (1) | JO3691B1 (hr) |
| LT (2) | LT3705488T (hr) |
| MX (4) | MX2016015532A (hr) |
| PH (1) | PH12016502342A1 (hr) |
| PL (2) | PL3705488T3 (hr) |
| PT (2) | PT3705488T (hr) |
| RS (2) | RS60529B1 (hr) |
| RU (2) | RU2699359C2 (hr) |
| SG (2) | SG11201609813XA (hr) |
| SI (2) | SI3705488T1 (hr) |
| TW (1) | TW201625661A (hr) |
| WO (1) | WO2015180679A1 (hr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ568700A (en) | 2005-11-28 | 2012-03-30 | Marinus Pharmaceuticals | Solid stabilized particulate formulations comprising ganaxolone |
| CN108976272B (zh) | 2011-10-14 | 2021-05-25 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| KR20230172622A (ko) | 2013-04-17 | 2023-12-22 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| HUE051403T2 (hu) | 2013-04-17 | 2021-03-01 | Sage Therapeutics Inc | Neuroaktív 19-nor-szteroidok kezelési eljárásokhoz |
| PT3021852T (pt) | 2013-07-19 | 2021-04-21 | Sage Therapeutics Inc | Esteroides neuroativos, composições e utilizações das mesmas |
| CA2921512A1 (en) | 2013-08-23 | 2015-02-26 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| HRP20221294T1 (hr) * | 2014-05-29 | 2023-03-03 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, njihovi pripravci i uporabe |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10577390B2 (en) | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| HUE051488T2 (hu) | 2014-10-16 | 2021-03-01 | Sage Therapeutics Inc | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére |
| EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
| DK3250210T3 (da) | 2015-01-26 | 2021-03-08 | Sage Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser |
| US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10780099B2 (en) | 2015-10-16 | 2020-09-22 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| MA43815A (fr) * | 2016-03-08 | 2021-04-07 | Sage Therapeutics Inc | Stéroïdes neuroactifs, compositions, et leurs utilisations |
| AU2017296295B2 (en) * | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| RU2019103590A (ru) * | 2016-07-11 | 2021-02-11 | Сейдж Терапьютикс, Инк. | С17-, с20- и с21-замещенные нейроактивные стероиды и способы их применения |
| KR20230050474A (ko) | 2016-08-11 | 2023-04-14 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| BR112020016269A2 (pt) | 2018-02-11 | 2020-12-15 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Reguladores derivados de esteroides, método para prepará- los e suas utilizações |
| CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| KR20210116523A (ko) * | 2019-01-14 | 2021-09-27 | 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 | 테트라졸론 치환된 스테로이드 및 이의 용도 |
| JP2022534424A (ja) | 2019-05-31 | 2022-07-29 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| JP2022543837A (ja) | 2019-08-05 | 2022-10-14 | マリナス ファーマシューティカルズ， インコーポレイテッド | てんかん重積状態の治療に使用するためのガナキソロン |
| KR20220066262A (ko) | 2019-08-07 | 2022-05-24 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 스테로이드 유도체 조절제의 염 및 결정형 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| JP2023503928A (ja) | 2019-12-06 | 2023-02-01 | マリナス ファーマシューティカルズ， インコーポレイテッド | 結節性硬化症の治療での使用のためのガナキソロン |
| WO2022165017A1 (en) | 2021-01-28 | 2022-08-04 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| KR20240037975A (ko) | 2021-07-28 | 2024-03-22 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드의 결정질 형태 |
| WO2023164387A1 (en) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
| WO2024026337A1 (en) | 2022-07-27 | 2024-02-01 | Sage Therapeutics, Inc. | Crystalline forms of a neuroactive steroid |
| WO2024059608A1 (en) | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Deuterated neuroactive steroids |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3634717A1 (de) * | 1986-10-11 | 1988-04-14 | Dynamit Nobel Ag | Verfahren zur herstellung von 5-methyltetrazol |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| JP4066272B2 (ja) * | 1994-02-14 | 2008-03-26 | ユーロ‐セルティック エス． ア． | Ｇａｂａ受容体のアロステリックな調節のためのアンドロスタン及びプレグナン類 |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| CA2372342A1 (en) * | 1999-04-29 | 2000-11-09 | Derk J. Hogenkamp | 3.alpha.-hydroxy-3.beta. methoxymethyl-21-heterocycle substituted steroids with anesthetic activity |
| ATE537748T1 (de) * | 2002-10-15 | 2012-01-15 | Medtronic Inc | Medizinisches vorrichtungssystem zur bewertung von gemessenen neurologischen ereignissen |
| US7729773B2 (en) * | 2005-10-19 | 2010-06-01 | Advanced Neuromodualation Systems, Inc. | Neural stimulation and optical monitoring systems and methods |
| CN108976272B (zh) * | 2011-10-14 | 2021-05-25 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| HRP20221294T1 (hr) * | 2014-05-29 | 2023-03-03 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, njihovi pripravci i uporabe |
| HUE051488T2 (hu) * | 2014-10-16 | 2021-03-01 | Sage Therapeutics Inc | Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére |
-
2015
- 2015-05-29 HR HRP20221294TT patent/HRP20221294T1/hr unknown
- 2015-05-29 IL IL292461A patent/IL292461B2/en unknown
- 2015-05-29 RU RU2016151727A patent/RU2699359C2/ru active
- 2015-05-29 SG SG11201609813XA patent/SG11201609813XA/en unknown
- 2015-05-29 TW TW104117532A patent/TW201625661A/zh unknown
- 2015-05-29 LT LTEP20171670.1T patent/LT3705488T/lt unknown
- 2015-05-29 JP JP2016569716A patent/JP6652934B2/ja active Active
- 2015-05-29 EP EP20171670.1A patent/EP3705488B1/en active Active
- 2015-05-29 AR ARP150101717A patent/AR100691A1/es active IP Right Grant
- 2015-05-29 RS RS20200799A patent/RS60529B1/sr unknown
- 2015-05-29 DK DK20171670.1T patent/DK3705488T3/da active
- 2015-05-29 EP EP15799762.8A patent/EP3149018B1/en active Active
- 2015-05-29 HU HUE20171670A patent/HUE059829T2/hu unknown
- 2015-05-29 SG SG10201803812TA patent/SG10201803812TA/en unknown
- 2015-05-29 KR KR1020167036320A patent/KR102494061B1/ko active IP Right Grant
- 2015-05-29 LT LTEP15799762.8T patent/LT3149018T/lt unknown
- 2015-05-29 CN CN201580039652.9A patent/CN106661078A/zh active Pending
- 2015-05-29 PL PL20171670.1T patent/PL3705488T3/pl unknown
- 2015-05-29 RS RS20220848A patent/RS63554B1/sr unknown
- 2015-05-29 HU HUE15799762A patent/HUE050028T2/hu unknown
- 2015-05-29 SI SI201531879T patent/SI3705488T1/sl unknown
- 2015-05-29 ES ES15799762T patent/ES2805598T3/es active Active
- 2015-05-29 WO PCT/CN2015/080216 patent/WO2015180679A1/en active Application Filing
- 2015-05-29 KR KR1020247014858A patent/KR20240066304A/ko active Application Filing
- 2015-05-29 AU AU2015266447A patent/AU2015266447A1/en not_active Abandoned
- 2015-05-29 PT PT201716701T patent/PT3705488T/pt unknown
- 2015-05-29 EP EP22187660.0A patent/EP4144746A1/en active Pending
- 2015-05-29 CN CN202111131937.9A patent/CN114133423A/zh active Pending
- 2015-05-29 PT PT157997628T patent/PT3149018T/pt unknown
- 2015-05-29 US US15/314,565 patent/US20180179247A1/en active Pending
- 2015-05-29 MX MX2016015532A patent/MX2016015532A/es unknown
- 2015-05-29 CN CN202110905603.6A patent/CN114369135A/zh active Pending
- 2015-05-29 CA CA2949720A patent/CA2949720A1/en active Pending
- 2015-05-29 ES ES20171670T patent/ES2927007T3/es active Active
- 2015-05-29 IL IL248948A patent/IL248948B/en unknown
- 2015-05-29 RU RU2019126637A patent/RU2019126637A/ru unknown
- 2015-05-29 IL IL304033A patent/IL304033A/en unknown
- 2015-05-29 DK DK15799762.8T patent/DK3149018T3/da active
- 2015-05-29 SI SI201531252T patent/SI3149018T1/sl unknown
- 2015-05-29 PL PL15799762T patent/PL3149018T3/pl unknown
- 2015-05-31 JO JOP/2015/0132A patent/JO3691B1/ar active
-
2016
- 2016-11-24 PH PH12016502342A patent/PH12016502342A1/en unknown
- 2016-11-25 MX MX2021005099A patent/MX2021005099A/es unknown
- 2016-11-25 MX MX2023004352A patent/MX2023004352A/es unknown
- 2016-11-25 MX MX2021005106A patent/MX2021005106A/es unknown
-
2019
- 2019-12-09 AU AU2019279910A patent/AU2019279910B2/en active Active
-
2020
- 2020-01-24 JP JP2020009771A patent/JP6892936B2/ja active Active
- 2020-01-31 US US16/778,975 patent/US20200165291A1/en not_active Abandoned
- 2020-07-17 HR HRP20201126TT patent/HRP20201126T1/hr unknown
- 2020-07-27 CY CY20201100683T patent/CY1124109T1/el unknown
- 2020-11-10 US US17/094,783 patent/US20210061849A1/en not_active Abandoned
- 2020-11-13 US US17/097,569 patent/US20210061850A1/en not_active Abandoned
-
2021
- 2021-03-25 AR ARP210100747A patent/AR121661A2/es unknown
- 2021-05-28 JP JP2021089953A patent/JP7386204B2/ja active Active
- 2021-06-28 AU AU2021204410A patent/AU2021204410B2/en active Active
-
2023
- 2023-07-10 JP JP2023113247A patent/JP2023123878A/ja active Pending
- 2023-10-06 US US18/482,079 patent/US20240076310A1/en active Pending
- 2023-12-19 AU AU2023285755A patent/AU2023285755A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221294T1 (hr) | Neuroaktivni steroidi, njihovi pripravci i uporabe | |
| HRP20210241T1 (hr) | Derivat policikličkog piridona protiv gripe i njegov predlijek | |
| HRP20171512T1 (hr) | Derivati betulina | |
| HRP20180591T1 (hr) | Inhibitori kinaze serina ili treonina | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| JP2019516735A5 (hr) | ||
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
| JP2017537066A5 (hr) | ||
| HRP20220759T1 (hr) | Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti | |
| WO2013188792A3 (en) | Neuroactive steroids, compositions, and uses thereof | |
| WO2011159550A3 (en) | Lysophosphatidic acid receptor antagonist and uses thereof | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| WO2015116856A3 (en) | Farnesoid x receptor antagonists | |
| SI2945620T1 (en) | Nitroxyl donors with improved therapeutic index | |
| JP2016510326A5 (hr) | ||
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| EA201592279A1 (ru) | Фармацевтическая композиция, ее получение и применение | |
| PH12015502406A1 (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
| HRP20180323T1 (hr) | Derivat kromona kao antagonist dopaminskog receptora d3 za njegovu upotrebu u liječenju spektra autističnih poremećaja | |
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| HRP20201187T1 (hr) | Derivat triazolopirazinona koristan kao inhibitor ljudskog pde1 |